Comprehensive Epigenomic Profiling from Plasma to Inform Therapy Selection, Cancer Biology & Drug Development
- Precede has developed a quantitative assay to measure tumor epigenomic expression of multiple genes using histone modifications indicative of promoter and enhancer activation as well as methylation
- Examples of application of this assay will be shown for ADC and RIC targets to predict response and to identify resistance mechanisms
- Furthermore, the assay can be used to measure estrogen receptor activation to predict response to SERDs